Repurposing drugs is not new to the pharmaceutical industry. In fact, according to a report from the Congressional Budget Office, approximately two-thirds of new drug applications submitted to the FDA are modifications of existing drugs or their indications. Drug lifecycle development often includes extending the value and lifetime of a drug through innovative means such as finding a new indication of an existing drug. In the following case study, Within3 created a virtual advisory board to help a top 25 pharmaceutical company conduct R&D to better understand the pros and cons of pursuing a new indication for an existing molecule. To learn more, complete the form to request our resource.
We were really surprised at the amount of detail we received. We are very happy with the online session.Brand Leader